ESMO Consensus Guidelines for management of patients with colon and rectal cancer. A personalized approach to clinical decision makingHans‐Joachim Schmoll, Andrés Cervantes, Eric Van Cutsem et al.|Annals of Oncology|2012Cited by 1.5k
Overall survival and clinical characteristics of pancreatic cancer in BRCA mutation carriersTalia Golan, Steven Gallinger, Zaheer Kanji et al.|British Journal of Cancer|2014Cited by 437
Distinguishing Features of Cetuximab and Panitumumab in Colorectal Cancer and Other Solid TumorsJesús García‐Foncillas, Sebastian Stintzing, Yu Sunakawa et al.|Frontiers in Oncology|2019Cited by 199
Consensus molecular subgroups (CMS) of colorectal cancer (CRC) and first-line efficacy of FOLFIRI plus cetuximab or bevacizumab in the FIRE3 (AIO KRK-0306) trialSebastian Stintzing, Volker Heinemann, Thomas Decker et al.|Annals of Oncology|2019Cited by 194
Assessing the prognostic value of carcinoembryonic antigen levels in stage I and II colon cancerOfer Margalit, Ben Boursi, Ronac Mamtani et al.|European Journal of Cancer|2018Cited by 48